Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Malaria Information and Prophylaxis, by Country [T]

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
CountryAreas with MalariaEstimated relative risk of Malaria for US Travelers2Drug Resistance3Malaria Species4Recommended Chemoprophlaxis5Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
TaiwanNoneNoneNot ApplicableNot ApplicableNot Applicable
TajikistanAll areas below 2,000 m (6,561 ft).Very LowChloroquineP. vivax 90%
P. falciparum 10%
Atovaquone-proguanil, doxycycline, mefloquine, or primaquine7
TanzaniaAll areas at altitudes below 1,800 m (5,906 ft)ModerateChloroquineP. falciparum >85%
P. ovale >10%
P. malariae, and P. vivax rare
Atovaquone-proguanil, doxycycline, or mefloquine
ThailandRural, forested areas that border Burma (Myanmar), Cambodia, and Laos. Rural, forested areas in districts of Phang Nga and Phuket. None in the cities of Bangkok, Chang Mai, Chang Rai, Koh Phangan, Koh Samui, Pattaya, Phang Nga, and Phuket.LowChloroquine and MefloquineP. falciparum 50% (up to 75% some areas)
P. vivax 50% (up to 60% some areas)
Remainder P. ovale
Atovaquone-proguanil or doxycycline
Timor-Leste (East Timor)AllNo dataChloroquineP. falciparum 50%
P. vivax 50%
P. ovale <1%
P. malariae <1%
Atovaquone-proguanil, doxycycline, or mefloquine
TogoAllHighChloroquineP. falciparum 85%
P. ovale 5-10%
Remainder P. vivax
Atovaquone-proguanil, doxycycline, or mefloquine
Tokelau (New Zealand)NoneNoneNot ApplicableNot ApplicableNot Applicable
TongaNoneNoneNot ApplicableNot ApplicableNot Applicable
Trinidad and TobagoNoneNoneNot ApplicableNot ApplicableNot Applicable
TunisiaNoneNoneNot ApplicableNot ApplicableNot Applicable
TurkeyPresent in southeastern part of the country. None on the Incerlik US Air Force Base and on typical cruise itineraries.Very LowNoneP. vivax predominantly
P. falciparum sporadically
Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, or primaquine7
TurkmenistanNoneNoneNot ApplicableNot ApplicableNot Applicable
Turks and Caicos Islands (U.K.)NoneNoneNot ApplicableNot ApplicableNot Applicable
TuvaluNoneNoneNot ApplicableNot ApplicableNot Applicable
  1. The information presented herein was accurate at the time of publication; however, factors that can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection, can markedly affect local malaria transmission patterns.
  2. This estimate of risk is based on numbers of cases of malaria reported in US travelers and the estimated volume of travel to these countries. In some instances the risk may be low because the actual intensity of transmission is low in that country. In other instances, significant malaria transmission may occur only in small focal areas of the country where US travelers seldom go. Thus even though the risk for the average traveler to that country may be low, the risk for the rare traveler going to the areas with higher transmission intensity will of course be higher. For some countries that are rarely visited by US travelers, there is insufficient information to make a risk estimate.
  3. Refers to P. falciparum malaria unless otherwise noted.
  4. Estimates of malaria species are based on best available data from multiple sources.
  5. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
  6. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
  7. Primaquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine. The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC-INFO